NetworkNewsWire Newsroom

Tuesday, November 3, 2020

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) May Help Bring Revitalization to the Mining District

- Mining district in Chile has been in sharp decline, hit particularly hard in 2020
- Government supports revitalization, has proposed a series of tax breaks for investors
- GOH drilling program anticipated to begin in January 2021
Formerly known as Altum Resources Corp, GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF) is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The company has entered into agreements to acquire seven promising gold projects. The company’s goal is to identify and capitalize on valuable precious metal projects in mineral-rich districts with stable political jurisdictions.
In April 2020, GoldHaven entered into an agreement to purchase the Rio Loa and the Coya projects. A few months later, in August, GOH entered into an agreement to acquire five potential gold projects in the same region of Northern Chile: the Alicia, Roma, Jacqueline, Valley and Condor projects.
The gold-rich Maricunga Belt, where all seven projects are located, straddles the border of Chile and Argentina. It is approximately 150 kilometers long and 30 kilometers wide. The mining district has seen a sharp decline over the last decade and has been hit particularly hard in 2020.
According to an article in the “Northern Miner” (https://nnw.fm/OUHI7), new projects in the area could bring revitalization to the Chilean economy, which has suffered greatly due to the coronavirus pandemic. The government is supportive of these efforts and wants to see these new jobs created. A series of tax breaks for investors has been proposed that includes instant depreciation of capital investments begun by December 2022 and a tax credit worth 25% of the salary of each new job created.
This government support of mining is not new. The Chilean Economic Development Agency launched an initiative over a decade ago to finance exploration projects in the country. A fund of $150 million was set aside to develop exploration and boost mining prosperity, with an end goal of becoming a world leader in the industry. To do so, the Chilean government began to promote investments that respected the environment, community and local workforce (https://nnw.fm/GvG4M). The government is looking for companies such as GoldHaven to come in and help revitalize the economy.
GOH has identified four of its seven properties (the Rio Loa, Coya, Alicia and Roma projects) as high-priority targets and plans to begin its drilling program in January 2021. These targets were identified through mapping, geochemical sampling, satellite imagery and location relative to existing discoveries.
For more information, visit the company’s website at www.GoldHavenResources.com.
NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://nnw.fm/ATUMF

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Sustainable Green Team Ltd. (SGTM) Subsidiary — Mulch Manufacturing — Awarded String of Contracts

Mulch Manufacturing has signed mulch supplier contract with Vero Beach, Florida
This — and other recent contracts — made possible due to SGTM’s recent completion of construction on its Florida Waste Management facility
Sustainable Green Team was created by bringing together three industry-leading companies

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, has announced that its wholly owned subsidiary will be the official mulch supplier for Vero Beach, Florida (https://nnw.fm/TH0av). Mulch Manufacturing has signed a one-year contract with the Florida city, with two additional one-year extensions.

The Vero Beach contract is the most recent in a string of contracts awarded to Mulch Manufacturing, one of the largest producers of packaged mulch products in the country. Earlier this month, the company obtained mulch contracts from three Circle K convenient store divisions (https://nnw.fm/KBhqS). A week earlier the SGTM subsidiary landed a mulch and soil purchase agreement with the Kroger Co. to provide material for the 94 stories in its Louisville, Kentucky division (https://nnw.fm/xJcoc). And that contract came on the heels of the company being awarded a 2021 mulch packaging contract renewal from Menards Inc. (https://nnw.fm/V1pyF).

“We are pleased to be awarded this new government contract opportunity,” said SGMT CEO and director Tony Raynor (https://nnw.fm/oq7aQ). “And it’s all thanks to our recently completed construction in the Waste Management (‘WM’) facility in central Florida.”

The July 2020 construction at the facility in Apopka, Florida, included a dual line mulch bagger and fully automated electric grinding screen operation. With the new fully electric equipment coming online, the company can increase its mulch production by four million bags per year within one shift. In addition, the new operations will allow full vertical integration at WM’s landfill by utilizing unused debris that is typically buried. Now the unused debris can be reused and branded into a premium mulch product onsite.

“This is a pivotal advancement,” said Raynor commented. “With our strong relationship with Waste Management, we are progressing toward achieving true green sustainability.

Mulch Manufacturing is part of the Sustainable Green Team LTD, which was created by combining the resources of three companies that were leaders In their specialties: Mulch Manufacturing, National Storm Recovery and Central Florida Arbor Care. As a result, SGMT has the expertise to address the needs of each of the combined customers with a new level of quality and cost effectiveness.

The Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling, and removal and bio-mass recycling, as well as manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

To learn more about the Sustainable Green Team, view the company’s investor presentation at http://nnw.fm/UpXmd. For more information about Mulch Manufacturing, visit www.MulchMfg.com.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://nnw.fm/SGTM

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Monday, November 2, 2020

CYBIN Corp. Set to Benefit from Growing Research, Interest in Psychedelics

Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education
Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre for Psychedelic Science
As an innovative company focusing on psilocybin, CYBIN is set to capitalize on growing academic, commercial attention

UC Berkeley is joining other prominent academic institutions, including Johns Hopkins University in Maryland and Imperial College in London, to accelerate the scientific research of psilocybin by launching a new center focusing on the compound (https://nnw.fm/ooMHq). As a mushroom life science company that expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited, CYBIN Corp. will benefit from the growing research interest in psilocybin, bringing the compound to the mainstream.

Five decades after a government ban on psychedelic research, UC Berkeley is opening its doors again to psychedelic science and public education. Supported by $1.25 million in seed funding from an anonymous donor, the prestigious university has announced the launch of the UC Berkeley Center for the Science of Psychedelics. The center aims to conduct research using psychedelics to explore cognition, perception, and emotion and their biological bases in the human brain. The center will also create a program to educate the public about the once-controversial and now rapidly advancing psychedelics research.

“There’s never been a better time to start a center like this. The renewal of basic and clinical science with psychedelics has catalyzed interest among many people,” said UC Berkeley neuroscientist David Presti, who is also one of the center’s co-founders.

Presti has teamed up with other co-founders to conduct studies and explore the potential of psilocybin and other psychedelic compounds. Their research will examine the effectiveness of treating highly prevalent mental disorders including anxiety, depression, post-traumatic stress disorder and substance abuse. Initial experimental studies will use psilocybin, the psychoactive compound found in “magic” mushrooms.

“Some of these studies have produced striking results in cases that are otherwise resistant to more conventional medical treatment. This suggests that psychedelic compounds may offer new hope for people suffering from these disorders,” said UC Berkeley neuroscientist Michael Silver, who also serves as an inaugural director of the newly launched Center for the Science of Psychedelics.

Likewise, Rotem Petranker, co-founder and director of the Canadian Centre for Psychedelic Science, is a clinical psychology PhD student with John Eastwood’s lab at York University (https://nnw.fm/kPUWX). His main research interests are sustained attention, emotional regulation and creativity, all of which are ostensibly affected by psychedelics. Petranker is passionate about establishing a rigorous framework for the study of psychedelics using open science principles. His clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and OCD.

Pretranker’s partner, co-founder and director Thomas Anderson, is a PhD candidate studying cognitive neuroscience at the University of Toronto in Canada. Anderson is a strong proponent of open science and publicly communicating scientific findings.

Dedicated to supporting clinical studies across North America and other regions through strategic academic and institutional partnerships, including the Canadian Centre for Psychedelic Science, CYBIN Corp. is poised to benefit from the increasing research interest in psilocybin. As an early entrant into a rapidly growing field, CYBIN seems well positioned to leverage the growing recognition of psychedelic research leading to eventual public acceptance with the potential to propel the whole industry to the new level.

CYBIN is an innovator in the stagnant pharmaceutical market, where it aims to become the first life science company to bring psiloybin medicine targeting major depressive disorder to market (http://nnw.fm/OIRiA).

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBIN are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Knightscope, Inc. Creating Change in the Security Industry Through Proprietary Technology to Assist Law Enforcement and Private Security

Knightscope recently named Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer
The company’s autonomous security robots use proprietary technology, combining robotics, self-driving capabilities, and artificial intelligence
Game changing technology has now been in operation over 1 million hours and is operating across 5 time zones 24/7/365

Knightscope is a leader in the development of autonomous security capabilities. The company designs and builds Autonomous Security Robots (“ASRs”), which use Knightscope’s proprietary technology combining robotics, self-driving technologies, and artificial intelligence.

The ASRs have proven to enhance the safety at hospitals, manufacturing plants, logistics facilities, schools, businesses, parking lots, and corporate campuses. This level of versatility enables Knightscope to disrupt the $500 billion security industry by offering reliable and cost-effective security solutions for a wide range of scenarios and locations – even during a pandemic. Knightscope currently has three models on the market, with one currently in long-term development – which all drive over 90 terabytes a year of data per machine to an intuitive browser-based user interface.

K1 ASR – The K1 ASR is the 2018 Security Today New Product of the Year award winner. The K1 is a stationary indoor/outdoor unit that can be put in high-risk areas, lobby and reception areas, and parking lots. The K1 runs 24/7 and can be used at help and assistance points using the two-way intercom feature.
K3 ASR – The K3 is an autonomously recharging indoor patrol ASR. The K3 is fully integrated with the Knightscope Security Operations Center (“KSOC”). Which makes it the smart eyes and ears of malls, warehouses, hospitals, offices, and several other locations where indoor patrol is optimal.
K5 ASR – Primarily used outdoors, the K5 features the KSOC technology and autonomously recharges itself as well. It has been in operation for over 1 million hours and worked through its third winter, and still going strong.
K7 ASR – The K7 is the latest ASR under development. This ASR is planned to handle rougher terrain, making it great for airports, utilities, federal government facilities, and many others. The ASR is also planned to be fully integrated with the KSOC user interface technology.
KSOC – the Knightscope Security Operations Center (“KSOC”) is the browser-based user interface our clients utilize to have the magic of our technology at their fingertips.

Providing real-time access to data around the clock, KSOC also features 360-degree eye-level HD video streaming, people detection, facial recognition, automatic license plate recognition, thermal anomaly detection, and automatic signal detection. The technology is also available to schedule patrols, maintain autonomous charging, analytics, live audio broadcast, two-way intercom, pre-recorded broadcast messages, and the capability to conduct investigations as well as obtain court admissible evidence.

Since Knightscope’s inception, it has raised over $70 million with over 16,000 investors. In preparation for a potential public listing, the company is in the process of raising an additional $25 million. It has already reserved the NASDAQ ticker symbol “KSCP.”

The company recently appointed Ms. Mallorie Burak as Executive Vice President and Chief Financial Officer. Ms. Burak is an experienced financial executive with over 25 years of expertise in many industries that range from early-stage start-ups to multi-national corporations. Ms. Burak’s previous experience includes CFO for ThinFilms Electronics ASA and many other industry leaders in which she held the CFO title. She has a proven track record of creating a high-performing culture with a focus on operational excellence (https://nnw.fm/hYuei).

Knightscope’s core mission is to make the United States of America the safest nation in the world. Through its innovative, proprietary technology, the company plans on supporting the millions of law enforcement and security professionals across the country.

For more information, visit the company’s website at www.Knightscope.com

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder

Study results have exciting therapeutic potential across wide range of CNS indications.
VTGN focused on developing new generation of medications to treat anxiety, depression and more.
Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression.

Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics. The company has released data from a second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. The results, which complement findings from a prior preclinical study, indicate that AV-101, when combined with probenecid, substantially increased the brain concentration of its active metabolite, 7-Cl-KYNA, a potent and selective full antagonist of the N-methyl-D-aspartate receptor (NMDAr) glycine co-agonist site. The combination of drugs may therefore reduce rather than block NMDAr signaling—an effect which could carry significant therapeutic potential.

“These new positive results amplify our message that AV-101, when administered in combination with probenecid, has exciting therapeutic potential across a wide range of CNS (central nervous system) indications,” said VistaGen CEO Shawn Singh. “The studies completed to date are promising and will help us determine the best next step in our overall development plan for the combination.”

VistaGen is assessing the potential of the AV-101/probenecid combination as a treatment for multiple CNS disorders, including dyskinesia (unwanted movement) associated with levodopa therapy for Parkinson’s disease, epilepsy, major depressive disorder, neuropathic pain and suicidal ideation (thoughts and behaviors).The company’s efforts currently are focused on developing three new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates, AV-101, PH10 and PH94B, has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://nnw.fm/VTGN

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

CNS Pharmaceuticals (NASDAQ: CNSP) Announces Completion of Drug Manufacturing for Brain Cancer Trial

Houston-based CNS Pharmaceuticals is preparing to launch Phase 2 clinical testing of a novel brain cancer-fighting drug candidate called Berubicin early next year
The biopharmaceutical company recently announced that a U.S.-based company contracted to make Berubicin has completed its production process and an Italian company working on a dual track in Europe is expected to finish by the end of the year
Berubicin has shown promise in combatting Glioblastoma multiforme, an aggressive form of brain cancer commonly regarded as incurable. One participant in Berubicin’s Phase 1 trial remains cancer-free 14 years after the trial
CNS Pharmaceuticals, with its sublicensee partner WPD Pharmaceuticals, is also preparing for 2 clinical trials in Poland including the first Phase 1 pediatric trial of Berubicin and a parallel Phase 2 trial in adults

The U.S. manufacturer for a novel anthracycline being tested by biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as a potential new strategy in combatting an inexorable and ultimately fatal type of brain tumor has completed the manufacturing process for the drug candidate, known as Berubicin.

CNS Pharmaceutical engaged Pharmaceutics International, Inc. (“Pii”) to make Berubicin in the United States while BSP Pharmaceuticals S.p.A. (“BSP“) worked on a dual track to make Berubicin in Italy under the company’s strategy of supplying its upcoming Phase 2 trials with sufficient quantities of the orphan drug status product amid the risk of delays in production and shipping as a result of the ongoing COVID-19 pandemic.

Completion of both Pii’s and BSP’s manufacturing of Berubicin moves CNS Pharmaceuticals closer to completing its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) to fight glioblastoma.

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer that has no known cure, however the Phase 1 trial of Berubicin in 2006 produced some promising results. Of 25 trial participants who were evaluated, 44 percent achieved what the company refers to as “statistically significant improvement in clinical benefit” (https://nnw.fm/c5Iay) while one patient has remained completely cancer-free as of the last evaluation on Feb. 20 — some 14 years after the initial trial phase.

Glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, although the drug temozolomide has been shown effective in temporarily extending the lifespan of fewer than 40 percent of the GBM patients with a specific genetic variation. The persistent cancer tends to recur after surgery and to develop a resistance to temozolomide over time, making an effective therapy in treating it an attractive goal.

The orphan drug designation grants Berubicin certain benefits during its development and provides CNS with the potential for market exclusivity if the drug is approved for combatting malignant gliomas.

“We are extremely pleased to achieve yet another milestone in our preparation efforts and demonstrate our continued ability to execute upon both our operational and clinical strategies in a timely and proficient manner,” CEO John Climaco stated in the news release. “We remain committed to further progressing our trial preparations, as we look forward to initiating a U.S. Phase 2 trial for Berubicin during the first quarter of 2021.”

As further evidence of the company’s progress toward advancing its clinical testing, CNS has contracted with Worldwide Clinical Trials as the research organization, Image Analysis Group as the imaging partner and with Berry Consultants as a biostatistical adviser for its Phase 2 trial design. CNS has also added renowned neuro-oncologist Dr. Patrick Wen to its Scientific Advisory Board.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP

About NetworkNewsWire

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Achieves Debt-Free Milestone, Provides ‘Clean Slate’ for Increased Uranium Production

One of few uranium, natural resource companies in North America with no debt
Sets stage for increasing uranium production as markets improve; launching rare earth element initiative
Allows rare earth production as markets warrant
Applauds U.S. government for securing agreement to limit imports of uranium from Russia

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium mining company in the United States, has officially reached debt-free status, a goal it has been working toward for the past several months (https://nnw.fm/VHKzE). The company reached that goal following the retirement of its remaining Cdn$10.4 million of floating rate convertible unsecured subordinated debentures; the company currently has no other remaining short- or long-term debt.

“While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free,” Energy Fuels president and CEO Mark S. Chalmers stated. “Being debt-free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing.”

Energy Fuel offers a truly unique portfolio that includes more licensed and constructed production capacity, mines and in-ground uranium resources than any other producer in the United States. The company has also developed diverse cash-flow-generating opportunities, including vanadium production and uranium recycling. And the company is making excellent commercial and technical progress on rare earth element processing.

“We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company,” Chalmers said. “Critical minerals, including uranium, rare earth elements and vanadium, are front and center in the U.S. right now, including bipartisan support in the U.S. government. We are continuing to work with our allies in the administration and Congress to create a strategic U.S. uranium reserve to enhance national security and energy security. As the leading uranium miner in the U.S., with more production facilities, capacity, expertise and in-ground resources than any other U.S. uranium producer, we expect to be one of the prime beneficiaries of any U.S. government support.”

Chalmers also stated that the company was pleased that the U.S. Department of Commerce was able to reduce uranium and nuclear fuel imports into the U.S. from Russia over the long term. “President Trump’s executive orders on critical minerals . . . may be an important step toward the U.S. government providing tangible support and/or funding to producers and processors of critical minerals, including the uranium and vanadium we currently produce, and the rare earth elements we hope to produce in the future,” Chalmers said.

“And of course, global uranium markets, where spot prices are up over 20% this year, appear poised to continue their bounce back, due to significant global production cutbacks and the fact that current spot and term pricing cannot sustain new or existing primary supply,” he continued. “Energy Fuels has created a number of significant, potentially ‘game-changing,’ catalysts while also maintaining a strong working capital position and eliminating debt. We look forward to continuing to provide updates in the coming weeks and months on several of these initiatives.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (“ISR”) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah — the only conventional uranium mill operating in the United States today. Together these assets have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era where the U.S. energy industry is moving toward zero-carbon sources of electricity, including nuclear.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://nnw.fm/UUUU

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.